arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive Leaguearthyper-975Research ArticleОБЗОРЫREVIEWSРоль амлодипина в лечении артериальной гипертензииЧерныхТ. М.noemail@neicon.ruЖуравлеваМ. В.noemail@neicon.ruАлееваГ. Н.noemail@neicon.ruВоронежская государственная медицинская академия им. Н.Н. Бурденко; ММА им. И.М. СеченоваРоссия200528042005112102104Copyright © Черных Т.М., Журавлева М.В., Алеева Г.Н., 20052005Черных Т.М., Журавлева М.В., Алеева Г.Н.Черных Т.М., Журавлева М.В., Алеева Г.Н.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/975ReferencesПрофилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.ALLHАТ Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002: 288: 2981-97.ALLHАТ Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002: 288: 2981-97.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004: 363 (9426): 2022-3.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004: 363 (9426): 2022-3.Liao Y., Asakura V., Takashima S. et al. Amlodipin ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation. Biochem Biophys Pes Commun 2005; 327 (4): 1083-7.Liao Y., Asakura V., Takashima S. et al. Amlodipin ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation. Biochem Biophys Pes Commun 2005; 327 (4): 1083-7.Deanfield J., Detiy J., Lichtlen P. et al. Amlodipine reduces transient myocardial ishemia in patients With coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24 (6): 1460-7.Deanfield J., Detiy J., Lichtlen P. et al. Amlodipine reduces transient myocardial ishemia in patients With coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24 (6): 1460-7.Deanfeald J.E., Detry J.M., Sellier P. et al. Medical treatment of myocardial ischemia in coronary artery diasease: effect of drug regime and irregual dosing in the CAPE II trial. J Am Coll Cardiol 2002: 40 (5): 917-25.Deanfeald J.E., Detry J.M., Sellier P. et al. Medical treatment of myocardial ischemia in coronary artery diasease: effect of drug regime and irregual dosing in the CAPE II trial. J Am Coll Cardiol 2002: 40 (5): 917-25.Packer M., O'Connor C., Ghali J. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survial Evaluation Study Group. N Engl J Med 1996; 335 (15): 1107-14.Packer M., O'Connor C., Ghali J. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survial Evaluation Study Group. N Engl J Med 1996; 335 (15): 1107-14.Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M., editor. Calcium antagonists in clinical medicine. 3 rd edition. Philadelphia: Hanky and Belfus: 2002: p. 293-313.Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M., editor. Calcium antagonists in clinical medicine. 3 rd edition. Philadelphia: Hanky and Belfus: 2002: p. 293-313.Hayashi K., Ozawa Y., Saruta T., Epstein M. Renal hemodynamic effects of calcium antagonists. In: Epstein M., editor. Calcium antagonists in clinical medicine. 3 rd edition. Philadelphia: Hanley and Belfus: 2002: p. 559-78.Hayashi K., Ozawa Y., Saruta T., Epstein M. Renal hemodynamic effects of calcium antagonists. In: Epstein M., editor. Calcium antagonists in clinical medicine. 3 rd edition. Philadelphia: Hanley and Belfus: 2002: p. 559-78.Lea J., Green T., Hebert L. el al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005:165 (8): 947-53.Lea J., Green T., Hebert L. el al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005:165 (8): 947-53.Pitt B., Byington R.P., Rurberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000: 102: 1503-10.Pitt B., Byington R.P., Rurberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000: 102: 1503-10.Jorgensen B., Simonsen S., Endresen К. et al. Restenosis and clinical out-com in patients treated with amlodipine after angioplasty: results from the Coronary Angio Plasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000; 35 (3): 592-9.Jorgensen B., Simonsen S., Endresen К. et al. Restenosis and clinical out-com in patients treated with amlodipine after angioplasty: results from the Coronary Angio Plasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000; 35 (3): 592-9.Nissen S.E., Tuzci E.M., Libbi P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004: 292 (18): 2217-25.Nissen S.E., Tuzci E.M., Libbi P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004: 292 (18): 2217-25.Terpstra W.F., May J.F., Smit A.J. et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004: 22 (7): 1309-16.Terpstra W.F., May J.F., Smit A.J. et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004: 22 (7): 1309-16.Seccia T.M., Vulpis V., Ricci S. et al. Antihypertensive and metabolic effect of amlodipine in patients with non-insulindependent diabetes mellitus. Clin Drue Invest 1995; 9 (1): 16-21.Seccia T.M., Vulpis V., Ricci S. et al. Antihypertensive and metabolic effect of amlodipine in patients with non-insulindependent diabetes mellitus. Clin Drue Invest 1995; 9 (1): 16-21.Ziesche K., Petkov V., Lambers С. el al. The calcium channel blocker amlodipin experts its anti-proliferative action via p 21 (Walf/cip I) gene activation. FASEB J 2004: 18 (13): 1516-23.Ziesche K., Petkov V., Lambers С. el al. The calcium channel blocker amlodipin experts its anti-proliferative action via p 21 (Walf/cip I) gene activation. FASEB J 2004: 18 (13): 1516-23.Kahn M.B., Boesze-Battaglia K., Stepp D.W. et al. Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine. Am J Physiol Heart Circ Physiol 2005: 288 (2): H 591-600.Kahn M.B., Boesze-Battaglia K., Stepp D.W. et al. Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine. Am J Physiol Heart Circ Physiol 2005: 288 (2): H 591-600.Ganafa A.A., Walton M., Eatman D. et al. Amlodipin attenuates oxidative stress-induced hypertension. Am J Hypertens 2004; 17 (9): 743-8.Ganafa A.A., Walton M., Eatman D. et al. Amlodipin attenuates oxidative stress-induced hypertension. Am J Hypertens 2004; 17 (9): 743-8.Picca M., Bisceglia J., Zocca et at. Effects of enalapril and amlodipine on left ventricular hypertrophy and (unction in essential hypertension. Clin Drug Invest 1997: 13 (Suppl. 1): 29-35.Picca M., Bisceglia J., Zocca et at. Effects of enalapril and amlodipine on left ventricular hypertrophy and (unction in essential hypertension. Clin Drug Invest 1997: 13 (Suppl. 1): 29-35.Kloner R., Sowers J., DiBona G. et al. Sex- and age- related antihypertensive effects amlodipine / The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1990, 77 (9): 713-22.Kloner R., Sowers J., DiBona G. et al. Sex- and age- related antihypertensive effects amlodipine / The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1990, 77 (9): 713-22.
The authors declare that there are no conflicts of interest present.